Rubedo Life Sciences, a Sunnyvale, Calif.-based biopharmaceutical company committed to developing first-in-class therapies targeting senescent cells which drive age-related diseases, closed a $12M seed financing round.
The round was led by Khosla Ventures, with participation from Longevity Fund, Refactor Capital, Shanda and additional investors.
The company intends to use the funds to advance its lead candidates in respiratory diseases such as idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD), and advance preclinical candidates in oncology, followed by neurodegenerative conditions, skeletal muscle disorders and other age-related diseases. Rubedo plans to advance several compounds into IND-enabling studies in pulmonary diseases starting next year.
Led by Marco Quarta, CEO & Co-Founder, Rubedo Life Sciences is a biopharmaceutical company developing a broad portfolio of innovative therapies engineered to target cells which drive chronic age-related diseases. Our proprietary ALEMBIC™ drug discovery platform has engineered novel first-in-class small molecules designed to selectively target senescent cells, which play a key role in the progression of pulmonary, oncological, neurodegenerative, fibrotic and other chronic disorders.